BioNTech (BNTX) Ends Colorectal Trial As Fair Value Narrative Faces A Fresh Test
BioNTech (NasdaqGS:BNTX) just scrapped its Phase 2 colorectal cancer trial for autogene cevumeran after an independent board saw a survival imbalance and little chance that continuing would change the efficacy picture.
BioNTech’s recent setbacks in colorectal cancer and fresh FDA approval for its updated COMIRNATY XFG COVID-19 vaccine arrive against a mixed trading backdrop, with the share price at US$98.13 and momentum softening in the very short term yet remaining positive over the past quarter.
Scan beyond BioNTech’s headlines and compare how peers in similar high-risk, high-reward niches are priced using our curated list of 17 high quality undiscovered gems.
BioNTech still has a broad oncology and vaccines engine, yet the share price reflects mixed recent returns and a modest value score. Is that a fair tag for this kind of mRNA platform today?
Most Popular Narrative: 18.6% Undervalued
Compared with BioNTech’s most followed fair value estimate of $120.62, the recent close at $98.13 leaves a sizeable gap that the narrative ties directly to oncology execution and a long runway of development spending.
BioNTech remains in a heavy investment phase, with R&D expenses (€2.6–2.8 billion) and net losses (€387 million in Q2 2025) significantly outpacing revenues outside of COVID-19; delayed or unsuccessful late-stage trial outcomes or commercialization of oncology assets could extend this negative earnings trajectory and compress margins further. BioNTech's strategic pivot toward oncology exposes the company to substantial execution risks, including competition from other immunotherapy and mRNA platforms (e.g., Moderna, Pfizer, traditional pharma), potential delays in regulatory approvals, and failure to meet clinical endpoints, all of which could undermine future revenue streams and reduce long-term net margins.
Want to see how a loss making mRNA specialist still gets a double digit discount rate, shrinking revenue forecasts and a rich future earnings multiple baked into one story? The narrative leans heavily on oncology timelines, shifting margins and share dilution assumptions that most headline summaries barely touch.
Result: Fair Value of $120.62 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the whole setup for BioNTech could crack if oncology trial setbacks deepen the current €1.7b loss profile, or if COVID-19 vaccine revenues fade faster than expected.
Find out about the key risks to this BioNTech narrative.
Next Steps
Looking for more BioNTech investment ideas?
If BioNTech has your attention but you want options, use the Simply Wall Street screener to compare different return profiles, risk levels and balance sheet strength.
- Target resilient candidates that aim to reduce downside shocks by focusing on a 10 resilient stocks with low risk scores.
- Hunt for potential bargains where quality and pricing intersect through a curated set of 31 high quality undervalued stocks.
- Prioritise financial strength first and filter for companies with clean finances and durable funding using a list of solid balance sheet and fundamentals (24 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com